No matches
Pulmonology

ERS 2025 | The Knowns and Unknowns in the COPD Landscape

Join Profs. Dave Singh and Klaus Rabe as they examine the clinical relevance of exacerbations, lung function, symptoms, quality of life, and comorbidities in COPD, as well as the evolving concept of disease stability and what that could mean for treatment planning and the future of COPD care.
Dave Singh
Klaus Rabe
FBPhS, MD, FERS
Dave Singh +1 more

Related resources

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

expert video
Eosinophils as a Biomarker for Type 2 Asthma

Eosinophils as a Biomarker for Type 2 Asthma

expert video
ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

expert video
ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden

ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden

expert video
ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma

ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma

expert video
ERS 2024 | View From the Clinic: What Are the Clinical Consequences of Airway Remodeling?

ERS 2024 | View From the Clinic: What Are the Clinical Consequences of Airway Remodeling?

expert video
ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

expert video
What Are the Key Inflammatory Processes in Patients with COPD?

What Are the Key Inflammatory Processes in Patients with COPD?

expert video
FeNO as a Biomarker for Type 2 Asthma

FeNO as a Biomarker for Type 2 Asthma

expert video
IgE as a Biomarker for Type 2 Asthma

IgE as a Biomarker for Type 2 Asthma

expert video
Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction

Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction

Infographic
On-Treatment Clinical Remission in Asthma Patients Case Tool

On-Treatment Clinical Remission in Asthma Patients Case Tool

interactivity
Pediatric Asthma Patient Case Tool: Ash

Pediatric Asthma Patient Case Tool: Ash

interactivity
The Cycle of Inflammation in Adult Asthma

The Cycle of Inflammation in Adult Asthma

interactivity
Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

expert video
ADVENT On Air | Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond

ADVENT On Air | Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond

Podcast
ERS 2024 | Understanding the Complex Pathophysiology of COPD

ERS 2024 | Understanding the Complex Pathophysiology of COPD

expert video
What Is The COPD Vicious Cycle?

What Is The COPD Vicious Cycle?

expert video
Adult Asthma Interactive Patient Cases

Adult Asthma Interactive Patient Cases

interactivity
ADVENT On Air | Many Faces of COPD: From Phenotypes to Endotypes

ADVENT On Air | Many Faces of COPD: From Phenotypes to Endotypes

Podcast
How Can FeNO Measurement Improve Severe Asthma Management?

How Can FeNO Measurement Improve Severe Asthma Management?

expert video
GOLD Diagnosis and Assessment of COPD

GOLD Diagnosis and Assessment of COPD

videoanimation
Clinical Manifestations Associated With Airway Remodeling in Asthma

Clinical Manifestations Associated With Airway Remodeling in Asthma

expert video
Impact of Exacerbations in COPD

Impact of Exacerbations in COPD

expert video
Role of Type 2 Cytokines in Asthma and COPD

Role of Type 2 Cytokines in Asthma and COPD

expert video
Exacerbations Lead to Worsening Lung Function

Exacerbations Lead to Worsening Lung Function

expert video
Uncovering the Impact of Moderate COPD Exacerbations

Uncovering the Impact of Moderate COPD Exacerbations

interactivity
Lung Function Decline: Why it Matters and What’s at Stake for Patients

Lung Function Decline: Why it Matters and What’s at Stake for Patients

interactivity
Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

expert video
Mucus Plugging as a Potential Target in Asthma Management

Mucus Plugging as a Potential Target in Asthma Management

expert video
Multifaceted Role of IL-13 in Airway Remodeling

Multifaceted Role of IL-13 in Airway Remodeling

expert video
Pediatric Asthma Trajectory and Clinical Remission

Pediatric Asthma Trajectory and Clinical Remission

expert video
Screen depicting a mucus plug in the airways

A view into the Airway: The Pathophysiology and Clinical Relevance of Mucus Plugs in Asthma

videoanimation
Pathways to Disease: Inflammation in COPD

Pathways to Disease: Inflammation in COPD

interactivity
ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

expert video
ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease Remodeling

ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease Remodeling

expert video
Understanding IL-33: A Key Factor in COPD Pathogenesis

Understanding IL-33: A Key Factor in COPD Pathogenesis

interactivity
ERS 2024 | What Do We Know About IL-33 Genetics?

ERS 2024 | What Do We Know About IL-33 Genetics?

expert video
Compounded Burden of Co-existing Type 2 Airway Diseases

Compounded Burden of Co-existing Type 2 Airway Diseases

expert video
Spotlight on Type 2 Inflammation in the Upper and Lower Airways

Spotlight on Type 2 Inflammation in the Upper and Lower Airways

expert video
ADVENT On Air | Diving Deep: Exploring the Impact of Airway Remodeling in Severe Asthma

ADVENT On Air | Diving Deep: Exploring the Impact of Airway Remodeling in Severe Asthma

Podcast
ERS 2024 | A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation

ERS 2024 | A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation

expert video
ERS 2024 | Unraveling the Role of Type 2 Inflammation in COPD

ERS 2024 | Unraveling the Role of Type 2 Inflammation in COPD

expert video
The Burden in Patients with CRSwNP and Coexisting Asthma

The Burden in Patients with CRSwNP and Coexisting Asthma

expert video
ADVENT On Air | Disease Modification in Severe Asthma: Framework, Assessment, and Clinical Impact

ADVENT On Air | Disease Modification in Severe Asthma: Framework, Assessment, and Clinical Impact

Podcast
ADVENT On Air | Breath, Blood, and Beyond: The Prognostic Power of Biomarkers in Asthma Across Ages

ADVENT On Air | Breath, Blood, and Beyond: The Prognostic Power of Biomarkers in Asthma Across Ages

Podcast

Learning objectives

  • Recognize the clinical impact of exacerbations, lung function, symptoms, quality of life, and comorbidities in COPD
  • Discuss the evolving concept of disease stability and its potential role in treatment planning
  • Explore limitations in current evidence and the future direction of COPD care
Tags
exacerbationslung functionsymptomssymposiumquality of lifecomorbidities
MAT-US-2603533 v1.0-P Expiration Date: 01/31/2028

About these experts

Pulmonology
FBPhS, MD, FERS

Dave Singh

Respiratory Physician, Professor of Clinical Pharmacology and Respiratory Medicine |University of Manchester, Manchester, United Kingdom

Pulmonology
MD, PhD, FERS

Klaus Rabe

Professor of Pulmonary Medicine | University of Kiel; Director of the Department of Pneumology | LungClinic Grosshansdorf, Kiel, Germany

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-US-2305040 v4.0 – P Expiration Date: 10/16/2027

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region